Obesity and reproductive health: “nocturne” to modern comorbidity

Obesity and reproductive health: “nocturne” to modern comorbidity

Modern trends of human lifestyle changes contribute to the unparalleled increase in the incidence of some occupational diseases. And, despite the development of modern technologies and such a pronounced leap in social development, obesity remains an unresolved issue of mankind. Today, obesity repres...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mekan R. Orazov, Viktor E. Radzinsky, Vera E. Balan, Evgeny D. Dolgov
Format:	Article
Language:	English
Published:	LLC "MEDIAFORMAT" 2024-09-01
Series:	Клинический разбор в общей медицине
Subjects:	obesity endometrial cancer drug therapy liraglutide semaglutide
Online Access:	https://klin-razbor.ru/en/archive/2024/vol-5-9-2024/obesity-and-reproductive-health-nocturne-to-modern-comorbidity_6952/?element
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review
by: Serene Lee, et al.
Published: (2024-11-01)

EVALUATION OF THE EFFECTIVENESS OF THE HUMAN GLUCAGON-LIKE PEPTIDE-1 ANALOGUE LIRAGLUTIDE IN PATIENTS WITH GOUT AND METABOLICALLY UNHEALTHY OBESITY PHENOTYPE
by: E. V. Volgina, et al.
Published: (2023-09-01)

Hormone therapy for genitourinary syndrome of menopause: reality and prospects
by: Mekan R. Orazov, et al.
Published: (2024-09-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

The effects of liraglutide on the characteristics of blood parameters and testicular tissue induced diabetes and obesity in mice
by: Saied Mohammadzadeh, et al.
Published: (2024-08-01)

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01)

The “iron curtain” of anti-aging: what is behind it?
by: Mekan R. Orazov, et al.
Published: (2024-09-01)

Safety and evidence base of a combined oral contraceptive based on estherol and drospirenone: a brief summary
by: Mekan R. Orazov, et al.
Published: (2024-09-01)

Editorial: Insights in obesity: 2023
by: Katsunori Nonogaki
Published: (2024-11-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity
by: Mengyang Du, et al.
Published: (2024-12-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
by: Michela Del Prete, et al.
Published: (2025-01-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Spotlight on the Mechanism of Action of Semaglutide
by: Ilias Papakonstantinou, et al.
Published: (2024-12-01)

Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
by: Bea Campforts, et al.
Published: (2024-11-01)

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
by: Yang L, et al.
Published: (2024-11-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
by: Ammar Ahmed, et al.
Published: (2024-12-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Rodrigo O. Moreira, et al.
Published: (2024-12-01)

Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
by: Jhih-Wei Dai, et al.
Published: (2024-11-01)

Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway
by: Yingli Xuan, et al.
Published: (2024-12-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
by: Adnan Malik, et al.
Published: (2022-01-01)

New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survival via suppression of TXNIP/NLRP3 pyroptosis signaling in Streptozocin–Induced diabetes mellitestype-1 in rats
by: Amira Karam Khalifa, et al.
Published: (2024-10-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer
by: Zhendong Qin, et al.
Published: (2024-11-01)

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
by: Yuan-Yuan Xu, et al.
Published: (2024-09-01)

Metabolic profile of patients with coronary artery disease and comorbid obesity.
by: T. Maksymets, et al.
Published: (2018-05-01)

Modern concepts about the problem of endometrial infertility against the backdrop of the "thin endometrium" (literature review)
by: Tatiana M. Motovilova, et al.
Published: (2024-10-01)

Liraglutide and GLP-1(9–37) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3β/Nrf2 pathway and SMAD159/Hepcidin/FTH pathway
by: Chenqi Lu, et al.
Published: (2025-02-01)